RxDoctor Payments DataLook up a doctor →

Naveed Mahfooz, MD

Internal Medicine · Caro, MINPI 1780639450

Payments from drug & device makers

$745,961in general payments, 2019–2025

Across 859 payments — averaging $868.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$276K
  • Pfizer$136K
  • Esperion Therapeutics, Inc.$83K
  • GSK$76K
  • Bristol Myers Squibb$65K
  • AstraZeneca$23K
  • plus $87K from 54 others
$2,216in research payments, 2019–2025

Across 4 payments — averaging $553.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K
  • AbbVie$810

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron21$276,430
Pfizer46$135,804
Esperion Therapeutics, Inc.92$82,649
GSK36$76,042
Bristol Myers Squibb11$64,550
AstraZeneca(2 entities)43$23,432
Avanir Pharmaceuticals, Inc.7$22,966
Gilead7$18,769
Kowa Research Institute, Inc.10$15,825
Eli Lilly1$10,967
Noven Pharmaceuticals, Inc.18$8,983
Amgen(2 entities)56$1,094
Merck53$944
AbbVie(2 entities)52$741
Otsuka America Pharmaceutical, Inc.31$575
Lilly USA, LLC33$493
Corcept Therapeutics33$488
Novo Nordisk39$483
Boehringer Ingelheim21$390
Vanda Pharmaceuticals Inc.18$360
Philips North America LLC32$327
Lundbeck LLC14$296
Sunovion Pharmaceuticals Inc.19$279
Johnson & Johnson10$269
Bayer8$211
Xeris Pharmaceuticals, Inc.10$189
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)13$185
Nestle Healthcare Nutrition Inc.9$183
Novartis8$136
Teva Pharmaceuticals USA, Inc.7$129
Acadia Pharmaceuticals Inc7$121
Sumitomo Pharma America, Inc.6$121
Axsome Therapeutics, Inc.6$121
UCB, Inc.6$117
Astellas Pharma US Inc6$114
Amarin Pharma, Inc.8$112
Mylan Specialty L.p.6$83
Neurelis, Inc.5$81
Kyowa Kirin, Inc.4$74
Scpharmaceuticals Inc.4$66
Aimmune Therapeutics, Inc.3$61
Urovant Sciences Inc3$58
Sanofi-aventis U.S. LLC3$58
Abbott1$52
Neurocrine Biosciences, Inc.3$48
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$46
Takeda Pharmaceuticals U.S.A., Inc.2$45
Paratek Pharmaceuticals, Inc.2$38
Dexcom, Inc.2$30
Verona Pharma, Inc.1$29
Medtronic(2 entities)2$28
Boston Scientific1$26
Inspire Medical Systems, Inc.1$24
Smith+Nephew2$24
E.r. Squibb & Sons, L.L.C.1$20
Amneal Pharmaceuticals LLC1$19
Corium, LLC1$19
Shield Therapeutics Inc1$18
Indivior Inc.1$16
Baxter Healthcare1$15

How this compares

$745,961 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan →

Medicare billing

Part B allowed, 2024
$1,188,068
Medicare patients
1,584
Services billed
15,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Caro

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →